Experimental Pharmacological Investigations of Effects of Nifedipine on Atrioventricular Conduction in Comparison with Those of Other Coronary Vasodilators

  • N. Taira
  • S. Motomura
  • A. Narimatsu
  • T. Iijima
Conference paper


Pharmacological investigations carried out so far on the cardiovascular actions of nifedipine (Adalat) (VATER et al. [10]; HASHIMOTO et al. [6]) have revealed that nifedipine is the most potent coronary vasodilator ever synthesized. The mechanism of its vasodilator action has been ascribed to the calcium antagonistic action: inhibition of the transmembrane calcium influx of the vascular smooth muscle to reduce the tone (FLECKENSTEIN et al. [3]; GRUN and FLECKENSTEIN [4]). On the other hand, it has been suggested that the ionic channel operative in excitation of cells in the atrioventricular (A-V) junctional area concerned in the major delay of A-V conduction is a slow channel which allows the transmembrane inflow of calcium, sodium ions or both (ZIPES and MENDEZ [12]). A coronary vasodilator, verapamil, the mechanism of action of which has also been described as that of calcium antagonism (GRÜN and FLECKENSTEIN [4]), is able to block this slow channel and cause impairment of A-V conduction (ZIPES and FISCHER [11]). From a therapeutic point of view, however, the impairment of A-V conduction by coronary vasodilators is one of their untoward effects. Thus, it is worthy to examine whether nifedipine as a potent calcium antagonist might impair A-V conduction. The present study was carried out in an attempt to elucidate this point. To characterize the effect of nifedipine on A-V conduction, comparison was made with those of other coronary vasodilators—verapamil, diltiazem (SATO et al [9]), dipyridamole and dilazep. Diltiazem is thought to dilate the coronary vascular bed probably by a calcium antagonistic action (KIYOMOTO, personal communication), whereas dilazep is thought to do so by potentiation of the action of endogenous adenosine (BUYNISKI et al. [2]) like dipyridamole (BRETSCHNEIDER et al. [1]).


Manganese Rubber Respiration Adenosine Hydrochloride 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    BRETSCHNEIDER, H. J., FRANK, A., BERNARD, U., KOCHSIEK,K., SCHELER,F.: Die Wirkung eines Pyrimidopyrimidin-Derivates auf die Sauerstoffver s or gung des Herzmuskels. Arzneim.-Forsch. (Drug Res.) 9, 49–59 (1959).Google Scholar
  2. 2.
    BUYNISKI,J.P., LOSADA, M., BIERWAGEN,M.E., GARDIER,R.W.: Cerebral and coronary vascular effects of a symmetrical N,N’-disubstituted hexahydrodiazepine. J. Pharmacol. Exp. Ther. 181,522–528 (1972).PubMedGoogle Scholar
  3. 3.
    FLECKENSTEIN, A., TRITTHART,H., DÖRING,H.-J., BYON,K.Y.: BAY a 1040 – ein hochaktiver CA+ +-antagonistischer Inhibitor der elektro-mechanischen Koppelungsprozesse im Warmblüter-Myokard. Arzneim.-Forsch. (Drug Res.) 22,22–33 (1972).Google Scholar
  4. 4.
    GRÜN,G., FLECKENSTEIN,A.: Die elektromechanische Entkoppelung der glatten Gefäßmuskulatur als Grundprinzip der Coronardilatation durch 4-(2’-Nitrophenyl)-2,6-dimethyl-1,4-dihydr opyridin-3,5-dicarbonsäure-dimethylester (BAY a 1040, Nifedipine). Arzneim.-Forsch. (Drug Res.) 22, 334–344 (1972).Google Scholar
  5. 5.
    HAAS,H., HÄRTFELDER,A.: α-Isopropyl-α-[(N-methyl-N-homoveratryl)-γ-amino-propyl]-3,4-dimethoxyphenylacetonitryl, eine Substanz mit coronargefäßerweiternden Eigenschaften. Arzneim.-Forsch. (Drug Res.) 12,549–558 (1962).Google Scholar
  6. 6.
    HASHIMOTO,K., TAIRA,N., CHIBA,S., HASHIMOTO,K., ENDOH,M., KOKUBUN,M., KOKUBUN, H., IIJIMA,T., KIMURA,T., KUBOTA,K., OGURO,K.: Cardiohemodynamic effects of BAY a 1040 in the dog. Arzneim.-Forsch. (Drug Res.) 22,15–21 (1972).Google Scholar
  7. 7.
    HENSEL,I., BRETSCHNEIDER,H.J., KETTLER,D., KNOLL,D., KOCHSIEK,K., REPLOH,H.D., SPIECKERMANN,P.G., TAUCHERT,M.: Die Wirkung von l,4-Bis[3-(3,4,5-trimethoxybenzoyloxy)-propyl]-perhydro-l,4-diazepin-dihydrochlorid auf Herzstoffwechsel, Haemodynamik, Koronar- und Nierendurchblutung. Arzneim.-Forsch. (Drug Res.) 22, 652–663 (1972).Google Scholar
  8. 8.
    KRAYER,O., MANDOKI,J.J., MENDEZ,C.: Studies on veratrum alkaloids. XVI. The action of epinephrine and of veratramine on the functional refractory period of the auriculoventricular transmission in the heart-lung preparation of the dog. J. Pharmacol. Exp. Ther. 103,412–419(1951).PubMedGoogle Scholar
  9. 9.
    SATO,M., NAGAO,T., YAMAGUCHI,I., NAKAJIMA,H., KIYOMOTO,A.: Pharmacological studies on a new 1,5-benzothiazepine derivative (CRD-401). I. Cardiovascular actions. Arzneim.-Forsch. (Drug Res.) 21,1338–1343 (1971).Google Scholar
  10. 10.
    VATER,W., KRONEBERG,G., HOFFMEISTER,F., KALLER,H., MENG,K., OBERDORF,A., PULS, W., SCHLOSSMANN, K., STOEPEL.K.: Zur Pharmakologie von 4-(2’-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester (Nifedipine, BAY a 1040). Arzneim.-Forsch. (Drug Res.) 22,1–14 (1972).Google Scholar
  11. 11.
    ZIPES,D.P., FISCHER,J.C.: Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog. Circulation Res. 34, 184–192 (1974).PubMedGoogle Scholar
  12. 12.
    ZIPES,D.P., MENDEZ,C.: Action of manganese ions and tetrodotoxin on atrioventricular nodal transmembrane potentials in isolated rabbit hearts. Circulation Res. 32, 447–454 (1973).PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1975

Authors and Affiliations

  • N. Taira
    • 1
  • S. Motomura
    • 1
  • A. Narimatsu
    • 1
  • T. Iijima
    • 1
  1. 1.Department of Pharmacology and Experimental TherapeuticsTohoku University School of MedicineSendaiJapan

Personalised recommendations